Crystal forms of β-nicotinamide mononucleotide
Crystalline forms of NMN, such as Form 1 and Form 2, address the need for improved NMN compositions by enhancing therapeutic efficacy and enabling intravenous use, effectively treating age-related and neurological conditions.
Patent Information
- Application Number
- JP2024111468
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2015-10-02
- Filing Date
- 2024-07-11
- Publication Date
- 2024-11-19
AI Technical Summary
There is a need for improved compositions and manufacturing methods of β-nicotinamide mononucleotide (NMN) to enhance its therapeutic benefits, particularly in treating age-related degenerative changes and ocular function, and to address challenges in formulating compositions suitable for intravenous use.
The development of crystalline forms of NMN, specifically Form 1 and Form 2, characterized by distinct XRD patterns, which are anhydrous or DMSO solvated, and methods for their production involving crystallization from specific solvents and antisolvents, ensuring high purity and low pyrogenic activity.
The crystalline forms of NMN provide enhanced therapeutic efficacy, allowing for effective treatment of age-related conditions and conditions affecting the central and peripheral nervous systems, while being suitable for intravenous administration.
Smart Images

Figure 2024161353000014 
Figure 2024161353000015 
Figure 2024161353000016
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 236,657, filed October 2, 2015, which is incorporated herein by reference in its entirety. [Background technology]
[0002] β-nicotinamide mononucleotide (NMN) has recently attracted attention for its use in treating, ameliorating, mitigating, slowing, halting, preventing and / or reversing age-related degenerative changes, such as age-related obesity, age-related increases in blood lipid levels, age-related decline in insulin sensitivity, age-related decline in memory function, and age-related changes in ocular function, such as macular degeneration. Summary of the Invention [Problem to be solved by the invention]
[0003] Given the therapeutic benefits associated with this compound, there is a need for improved compositions of NMN. Additionally, there is a need for improved methods of producing and formulating β-nicotinamide mononucleotide. [Means for solving the problem]
[0004] One aspect of the present invention is a compound represented by formula (I) [ka] The present invention relates to a crystalline compound having the structure:
[0005] Another aspect of the present invention relates to a method for preparing the crystalline compound of formula (I).
[0006] In certain embodiments, the present invention provides a pharmaceutical preparation suitable for use in a human patient, the pharmaceutical preparation comprising a crystalline compound of formula (I) and one or more pharma- ceutically acceptable excipients. In certain embodiments, the pharmaceutical preparation may be used to treat or prevent a condition or disease described herein. In certain embodiments, the pharmaceutical preparation has sufficiently low pyrogenic activity that it is suitable for intravenous use in a human patient. [Brief description of the drawings]
[0007] [Figure 1] FIG. 1 shows the XRPD patterns of β-nicotinamide mononucleotide (NMN) Form 1 and Form 2. [Diagram 2] FIG. 1 shows a differential scanning calorimetry thermogram of Form 1. [Diagram 3] FIG. 2 shows a differential scanning calorimetry thermogram of Form 2. [Figure 4] FIG. 1H NMR spectra of amorphous NMN, NMN Form 1, and NMN Form 2 after drying under vacuum. As shown in the spectra, Form 1 is substantially anhydrous, while Form 2 has approximately 1.1-1.2 DMSO molecules for every molecule NMN. [Diagram 5] FIG. 1 shows a comparison of XRPD patterns of amorphous NMN, amorphous NMN after storage, and NMN Form 1. [Figure 6] FIG. 1 shows the dynamic water vapor sorption isotherm of amorphous NMN. [Figure 7] Figure 7 shows the dynamic water vapor sorption change in mass plot of amorphous NMN. When a sample of amorphous NMN is exposed to atmospheric humidity, the sample moves through phases. Figure 7 shows the mass change over time. Amorphous samples are hygroscopic until they dissolve and begin to crystallize. Weight loss in less than 1000 minutes indicates the crystallization phenomenon. Once crystallized, the material remains crystalline and retains the same XRPD pattern after two doubling cycles, but still exhibits the ability to reversibly regain mass (up to 9% w / w change). [Figure 8]1 is an image showing single crystals of NMN Form 1 observed under a polarizing microscope. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0008] In certain embodiments, the present invention provides a compound of formula (I): [ka] The present invention provides a crystalline compound having the structure:
[0009] In certain embodiments, the crystalline compound of formula (I) is not solvated (e.g., the crystal lattice does not contain molecules of a solvent). In certain embodiments, the crystalline compound of formula (I) is anhydrous or substantially anhydrous. In certain alternative embodiments, the crystalline compound of formula (I) is solvated. In certain such embodiments, the crystalline compound of formula (I) is a dimethylsulfoxide (DMSO) solvate.
[0010] Any of the crystalline compounds described herein may be used in the manufacture of a medicament for the treatment of any of the diseases or conditions disclosed herein.
[0011] In certain embodiments, the compounds of the present invention can form one or more crystals. In an exemplary embodiment, the crystalline compound having the structure of formula (I) exists as "Form 1" and "Form 2", which are described in detail below. These different forms are herein known as "polymorphs".
[0012] In certain embodiments, the polymorphs of the crystalline compounds are characterized by powder X-ray diffraction (XRD). θ represents the diffraction angle measured in degrees. In certain embodiments, the diffractometer using XRD measures the diffraction angle as two times the diffraction angle θ. Thus, in certain embodiments, the diffraction patterns described herein refer to the X-ray intensity measured versus the angle 2θ.
[0013] In certain embodiments, the anhydrous crystalline compound of formula (I) has 2θ values of 20.03, 20.14, 21.83, and 25.73. In further embodiments, the anhydrous crystalline compound has 2θ values of 20.03, 20.14, 21.03, 21.83, 23.08, 23.39, 25.73, and 26.59. In yet further embodiments, the anhydrous crystalline compound has 2θ values of 7.70, 11.54, 12.64, 16.03, 18.99, 20.03, 20.14, 20.83, 21.03, 21.83, 23.08, 23.39, 25.48, 25.73, 26.59, and 29.78. In still yet further embodiments, the anhydrous crystalline compound has 2θ values of 7.70, 9.95, 11.54, 12.64, 16.03, 18.18, 18.99, 19.16, 19.44, 20.03, 20.14, 20.83, 21.03, 21.83, 22.44, 23.08, 23.39, 23.89, 24.08, 24.53, 24.68, 25.05, 25.48, 25.73, 26.08, 26.59, 27.33, 27.67, 29.78, and 29.92.
[0014] In certain embodiments, the anhydrous crystalline compound of Formula (I) has an XRD pattern substantially as shown in FIG.
[0015] In certain embodiments, the crystalline compound of formula (I) is not solvated (e.g., the crystal lattice does not contain molecules of the solvent). In certain alternative embodiments, the crystalline compound of formula (I) is solvated.
[0016] In certain embodiments, the crystalline DMSO solvate of the compound of Formula (I) has 2θ values of 8.29, 17.39, 19.54, 22.78, and 22.98. In further embodiments, the crystalline DMSO solvate has 2θ values of 8.29, 17.39, 19.54, 19.74, 20.98, 21.58, 22.03, 22.78, 22.98, and 25.53. In still further embodiments, the crystalline DMSO solvate has 2θ values of 8.29, 16.10, 17.39, 19.24, 19.54, 19.74, 20.33, 20.78, 20.98, 21.18, 21.58, 22.03, 22.78, 22.98, 25.53, 28.48, and 29.48. In further embodiments, the crystalline DMSO solvate has 2θ values of 8.29, 13.12, 15.79, 16.10, 16.69, 17.39, 19.03, 19.24, 19.54, 19.74, 20.33, 20.78, 20.98, 21.18, 21.58, 22.03, 22.78, 22.98, 23.95, 24.14, 24.48, 24.64, 25.14, 25.53, 25.87, 26.89, 27.18, 27.67, 28.02, 28.13, 28.48, 28.98, 29.34, 29.48, and 29.92.
[0017] In certain embodiments, the crystalline DMSO solvate of the compound of formula (I) has an XRD pattern substantially as shown in FIG.
[0018] In certain embodiments, the crystalline DMSO solvate of the compound of formula (I) contains about 1.0, about 1.1, or about 1.2 molecules of DMSO per molecule of NMN.
[0019] In certain embodiments, the present invention relates to a pharmaceutical composition comprising a crystalline compound of formula (I) and one or more pharma- ceutically acceptable excipients, hi certain embodiments, the pharmaceutical composition is selected from a tablet, a capsule, and a suspension.
[0020] As used herein, the term "substantially pure" refers to a crystalline polymorph that is greater than 90% pure, meaning that it contains less than 10% of any other compound, including alternative polymorphs of the corresponding amorphous compound or crystalline salt. Preferably, the crystalline polymorph is greater than 95% pure, or even greater than 98% pure.
[0021] Methods for preparing crystalline forms of NMN In certain embodiments, the present invention relates to a method for preparing a crystalline compound having a structure of formula (I), comprising the steps of: a) providing a mixture of a compound of formula (I) in a solvent; and b) crystallizing the compound of formula (I) from the mixture comprising the compound of formula (I).
[0022] In certain embodiments, the mixture comprising the compound of Formula (I) is a solution, hi certain embodiments, the mixture is a slurry or a suspension.
[0023] In certain embodiments, the crystalline compounds made by the methods of the invention are anhydrous.
[0024] In certain embodiments, the crystalline compound made by the methods of the invention is a solvate, for example a DMSO solvate.
[0025] In certain embodiments, the mixture comprising the compound of formula (I) is a solution, and crystallizing the compound from the mixture comprises supersaturating the solution to cause the compound of formula (I) to precipitate from the solution.
[0026] In certain embodiments, the step of supersaturating the mixture containing the compound of formula (I) includes gently adding an anti-solvent, such as heptane, hexane, ethanol, or another polar or non-polar liquid miscible with the organic solvent, cooling the solution (with or without seeding), reducing the volume of the solution, or any combination thereof. In certain embodiments, the step of supersaturating the mixture containing the compound of formula (I) includes adding an anti-solvent, cooling the solution to below ambient temperature, and reducing the volume of the solution, for example, by evaporating the solvent from the solution. In certain embodiments, the step of cooling the solution can be passive (e.g., allowing the solution to stand at ambient temperature) or active (e.g., cooling the solution in an ice bath or freezer).
[0027] In certain embodiments, the method further comprises isolating the crystals, for example by filtering the crystals, by decanting the liquid from the crystals, or by any other suitable separation technique. In further embodiments, the method further comprises washing the crystals.
[0028] In certain embodiments, the manufacturing method further comprises inducing crystallization. The method may also comprise drying the crystals, for example under reduced pressure. In certain embodiments, inducing precipitation or crystallization comprises secondary nucleation, where nucleation occurs in the presence of seed crystals or upon interaction with the environment (crystallizer walls, stirring impellers, ultrasound, etc.).
[0029] In certain embodiments, the solvent comprises acetonitrile, N,N-dimethylacetamide (DMA), dimethylformamide (DMF), dimethylsulfoxide (DMSO), ethanol, ethyl acetate, heptane, hexane, isopropyl acetate, methanol, methyl ethyl ketone, N-methyl-2-pyrrolidone (NMP), tetrahydrofuran, toluene, 2-propanol, 1-butanol, water, or any combination thereof. In certain preferred embodiments, e.g., to achieve Form 1, the solvent is methanol or water. In other preferred embodiments, e.g., to achieve Form 2, the solvent is dimethylsulfoxide.
[0030] In certain embodiments, washing the crystals includes washing with a liquid selected from the anti-solvent, acetonitrile, ethanol, heptane, hexane, methanol, tetrahydrofuran, toluene, water, or a combination thereof. As used herein, "anti-solvent" refers to a solvent in which the salt crystals cannot be dissolved, can only be dissolved to a minimum, or can be partially dissolved. In practice, adding an anti-solvent to a solution in which the salt crystals are dissolved reduces the solubility of the salt crystals in the solution, thereby stimulating the precipitation of the salt. In certain embodiments, the crystals are washed with a combination of an anti-solvent and an organic solvent. In certain embodiments, the anti-solvent is water, while in other embodiments, the anti-solvent is an alkane solvent such as hexane or pentane, or an aromatic hydrocarbon solvent such as benzene, toluene, or xylene. In certain embodiments, the anti-solvent is methanol.
[0031] In certain embodiments, washing the crystals comprises washing the crystalline compound of Formula (I) with a solvent or a mixture of one or more solvents described above, hi certain embodiments, the solvent or mixture of solvents is cooled prior to washing.
[0032] In certain embodiments, the methods for making crystalline forms of NMN are used to remove one or more impurities from NMN. In certain embodiments, the crystallization methods described herein are used to purify NMN, for example, as a final purification step in the manufacture of a compound.
[0033] Use of Crystalline Forms of NMN NMN is produced from nicotinamide in the NAD biosynthetic pathway, a reaction catalyzed by Nampt. NMN is further converted to NAD in the NAD biosynthetic pathway, a reaction catalyzed by Nmnat. "Nicotinamide adenine dinucleotide" (NAD), which corresponds to the following structure: [ka] is produced from the conversion of nicotinamide to NMN, which is catalyzed by Nampt, followed by the conversion of NMN to NAD, which is catalyzed by Nmnat. In mammals, the functional homolog of yeast PNC1 is NAMPT, which also catalyzes the first step of NAD salvage. NAMPT catalyzes the formation of nicotinamide mononucleotide (NMN) from NAM, which is then converted to NAD by NMNAT1, NMNAT2, and NMNAT3. Nicotinamide riboside, the precursor of NAD, enters the salvage pathway after being converted to NMN by the nicotinamide riboside kinase (NRK) enzyme.
[0034] Thus, diseases, disorders, and conditions affected by increased NAD levels are similarly affected by the amount of NMN precursors capable of NAD biosynthesis, and therefore can be treated by administering the NMN compounds and compositions disclosed herein.
[0035] In certain embodiments, NMN acts through the nicotinamide mononucleotide adenylyltransferase (Nmnat1) pathway or other pathways of NAD+ biosynthesis with nutritional and / or therapeutic value in improving plasma lipid profiles, preventing stroke, and / or extending lifespan and well-being. Other embodiments relate to methods of preventing or treating diseases or conditions associated with the nicotinamide mononucleotide adenylyltransferase (Nmnat1) pathway or other pathways of NAD+ biosynthesis by administering a composition comprising NMN. Diseases or conditions that normally alter the levels of NAD+ or its precursors that can be prevented or treated by supplementing diets or therapeutic treatment regimens with NMN and / or NAD+ include, but are not limited to, lipid disorders (e.g., dyslipidemia, hypercholesterolemia, or hyperlipidemia), stroke, type I and type II diabetes, cardiovascular disease, and other physical problems associated with obesity.
[0036] Neurodegenerative diseases Axonal degeneration occurs frequently in neurodegenerative diseases and peripheral neuropathies. Degeneration of severed axons is delayed in Wallerian degeneration delayed (Wlds) mice that have overexpression of a fusion protein containing the nicotinamide adenine dinucleotide (NAD+) synthesizing enzyme, nicotinamide mononucleotide adenylyltransferase (Nmnat1). Both Wld and Nmnat1 function by themselves to prevent axonal degeneration in neuronal cultures.
[0037] NAD+ levels are reduced in injured, diseased or degenerated neurons, and prevention of this reduction in NAD+ effectively protects neurons from cell death. See Araki & Milbrandt, "Increased nuclear NAD+ biosynthesis and SIRT1 activation prevent axonal degeneration," Science. 2004 Aug. 13;305(5686):1010-3, and Wang et al., "A local mechanism mediates NAD-dependent protection of axon degeneration," J Cell Biol. 170(3):349-55 (2005), which are incorporated by reference in their entireties. Because NMN can increase intracellular levels of NAD+, NMN is useful as a therapeutic or nutritional supplement in the management of injuries, diseases and disorders affecting the central and peripheral nervous systems, including, but not limited to, trauma or injury to nerve cells, diseases or conditions that impair nerve cells, and neurodegenerative diseases or syndromes. The correlation between increased NAD+ synthesis and beneficial outcomes in nerve injuries and diseases or conditions is discussed, for example, in Stein et al., "Expression of Nampt in Hippocampal and Cortical Excitatory Neurons Is Critical for Cognitive Function," The Journal of Neuroscience 2014, 34(17):5800-5815, and Stein et al., "Specific ablation of Nampt in adult neural stem cells recapitulates their functional defects during aging," EMBO J. 2014, 33:1321-1340.
[0038] Some neurodegenerative diseases, neurodegenerative syndromes, diseases and conditions that impair or cause damage to nerve cells are described below.
[0039] Essential tremor (ET) is the most common movement disorder. It is a syndrome characterized by a slowly progressive, postural and / or kinetic tremor that usually affects both upper limbs.
[0040] Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with loss of dopaminergic nigrostriatal neurons.
[0041] Alzheimer's disease (AD) is the most common form of dementia. Alzheimer's disease is a progressive degenerative disease of the brain that is strongly associated with the progression of age. Over time, people with this disease lose the ability to think and reason clearly, evaluate situations, solve problems, concentrate, remember useful information, take care of themselves, and even speak. Some neurodegenerative diseases, such as Alzheimer's disease, exert their biological effects in the brain. The compounds disclosed herein based on nicotinamide mononucleotide are preferably capable of crossing the blood-brain barrier (BBB).
[0042] Huntington's disease (HD) is an adult-onset, incurable, autosomal dominant genetic disorder associated with cell loss within specific subranges of neurons in the basal ganglia and cortex.
[0043] Ataxia is defined as the inability to maintain normal posture and smoothness of movement. Neurological symptoms and signs, such as seizures and movement disorders (e.g., dystonia, chorea), may accompany ataxia.
[0044] Catatonia is a state of apparent unresponsiveness to external stimuli in an apparently awake person.
[0045] Epilepsy is defined as a chronic condition characterized by spontaneous, recurrent seizures. A seizure is defined as a clinical event associated with transient hypersynchronous neuronal discharges.
[0046] Neuroleptic malignant syndrome (NMS) refers to a combination of hyperpyrexia, rigidity and autonomic dysfunction that can occur as a serious complication of antipsychotic drug use.
[0047] Chorea is an abnormal involuntary movement characterized by sudden, brief, nonrhythmic, nonrepetitive movements of any limb, often accompanied by nonpatterned facial distortions. Chorea gravitationalis (CG) is the term given to chorea that occurs during pregnancy.
[0048] Clinical features of corticobasal degeneration (CBGD) include progressive dementia, parkinsonism, and limb apraxia. Dysfunction of central or peripheral nervous system pathways can lead to autonomic dysfunction.
[0049] Dystonia is a syndrome of sustained muscle contractions, usually resulting in twisting and repetitive movements or abnormal postures. Writer's cramp is a form of task-specific focal dystonia.
[0050] Mental Retardation (MR) is a condition in which intellectual abilities are severely limited. Developmental Disability refers to a condition in which an individual's ability to perform expected activities and roles in a certain social environment is limited. In many cases, MR and developmental disability coexist as a result of brain damage.
[0051] Neuroacanthocytosis is a progressive neurological disease characterized by movement disorders, personality changes, cognitive decline, axonal neuropathy, and seizures. Most patients have acanthocytosis on peripheral blood smears at some point during the course of the disease.
[0052] Pelizaeus-Merzbacher disease (PMD) and X-linked spastic paraplegia type 2 (SPG2) are at opposite ends of the clinical spectrum of X-linked disorders caused by mutations in the same gene, proteolipid protein 1 (PLP1), resulting in defects in myelination of the central nervous system (CNS). Clinical signs usually include some combination of nystagmus, inspiratory stridor, spastic quadriplegia, hypotension, cognitive impairment, ataxia, tremor, and diffuse leukoencephalopathy on MRI scans.
[0053] Progressive supranuclear palsy (PSP), also known as Steele-Richardson-Olszewski syndrome, is a neurodegenerative disorder that affects cognition, ocular coordination, and posture.
[0054] Striatonigral degeneration (SND) is a neurodegenerative disease that presents with symptoms of multiple system atrophy (MSA), other manifestations being Shy-Drager syndrome (e.g., predominantly autonomic neuropathy) and sporadic olivopontocerebellar degeneration (sOPCA, predominantly cerebellar).
[0055] Ischemic stroke occurs due to loss of blood supply to parts of the brain, initiating the ischemic cascade. If brain tissue is deprived of oxygen for more than 60-90 seconds, it stops functioning and after a few hours may suffer irreversible damage leading to tissue death, i.e., infarction. Atherosclerosis can interrupt blood supply by narrowing the lumen of blood vessels resulting in reduced blood flow, causing the formation of blood clots in blood vessels, or by rupture of atherosclerotic plaques releasing a shower of small emboli. Embolic infarction occurs when an embolus forms somewhere in the circulatory system, usually in the heart as a result of atrial fibrillation, or in the carotid arteries. These break off and enter the cerebral circulation, then lodge in and block cerebral vessels.
[0056] Due to collateral circulation within the area of brain tissue affected by ischemia, there is a range of severity. Thus, parts of tissue may die immediately, while other parts may merely be damaged and are able to recover. The ischemic area in which tissue recovers is called the ischemic penumbra.
[0057] As oxygen or glucose becomes depleted in ischemic brain tissue, production of high energy phosphate compounds such as adenine triphosphate (ATP) does not occur, resulting in failure of energy-dependent processes necessary for tissue cell survival. This initiates a series of interrelated events that result in cell injury and death. These include mitochondrial failure, which can lead to further energy depletion and can trigger cell death by apoptosis. Other processes include loss of membrane ion pump function, resulting in electrolyte imbalance in brain cells. There is also release of excitatory neurotransmitters, which have toxic effects in excessive concentrations.
[0058] Spinal cord injury or myelopathy is a disorder of the spinal cord that results in loss of sensation and mobility. There are two common types of spinal cord injury: trauma: automobile accidents, falls, gunshot wounds, diving accidents, etc., and disease: polio, spina bifida, tumors, Friedreich's ataxia, etc. It is important to note that the spinal cord does not have to be completely severed to lose function. In fact, the spinal cord remains intact in most cases of spinal cord injury.
[0059] Traumatic brain injury (TBI), also called intracranial injury or simply head injury, occurs when a sudden trauma causes brain damage. TBI can result from closed head trauma or penetrating head trauma and is one of two subcategories of acquired brain injury (ABI). The other subcategory is non-traumatic brain injury (e.g., stroke, meningitis, anoxia). Parts of the brain that can be damaged include the cerebral hemispheres, cerebellum, and cerebral pedicle. Symptoms of TBI can be mild, moderate, or severe, depending on the extent of the damage to the brain. Consequences can be anything from full recovery to permanent disability or death. Coma can also affect a child's brain. The damage resulting from TBI can be focalized to one area of the brain or can be dispersed, involving more than one area of the brain. Diffuse trauma to the brain is often associated with concussion (a concussion of the brain in response to a sudden movement of the head), diffuse axonal injury, or coma. Localized damage may be accompanied by neurobehavioral symptoms, hemiparesis, or other focal neurological deficits.
[0060] Another injury to the brain that can cause injury is anoxia. Anoxia is a condition in which there is a lack of oxygen delivery to organ tissues, even when there is adequate blood flow to the tissues. Hypoxia refers to a reduced oxygen supply, rather than a complete absence of oxygen, and ischemia is an inadequate blood supply, as seen when the brain swells. In either of these cases, without adequate oxygen, a biochemical cascade called the ischemic cascade goes off the hook and the cells of the brain can die within minutes. This type of injury is often seen in drowning victims, heart attack patients (especially those who have undergone cardiac arrest), or humans who have suffered significant blood loss due to other injuries, which then causes a reduction in blood flow to the brain due to circulatory (hypovolemic) shock.
[0061] Regulating blood glucose levels Provided herein are methods for regulating blood glucose levels in a mammal. As used herein, regulating blood glucose levels refers to either increasing, decreasing and / or maintaining blood glucose levels relative to previously determined levels.
[0062] NMN can be administered to a mammal in need of such treatment. For example, the mammal may need to increase blood glucose levels. Alternatively, the mammal may need to decrease blood glucose levels. Or the mammal may need to maintain blood glucose levels above, at or below a certain level, or within a certain range (e.g., by a series of increases and / or decreases, or without increases or decreases). NMN to regulate blood glucose levels may also be administered to a mammal as a preventative measure. That is, the mammal is in need of treatment to prevent or delay the onset or development of a medical condition, such as, for example, type 1 or type 2 diabetes.
[0063] The ability to modulate blood glucose levels in a mammal by the methods described herein (e.g., by administering to the mammal a blood glucose level modulating amount of a compound of the invention) can be advantageous in the treatment and / or prevention of various complications, disorders and / or diseases. The role of increasing NAD+ levels for metabolic diseases and conditions has been described, for example, in Yoshino et al., "Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes," Cell Metab. 2011, 14:528-536, and Garten et al., "Nampt: Linking NAD biology, metabolism, and cancer," Trends Endocrinol Metab. 2009, 20(3):130-138. In general, the present invention can be utilized to treat, either directly or indirectly, a variety of acute, intermediate, and chronic conditions that can be affected by systemic NAD biosynthesis.
[0064] For example, regulation of blood glucose concentrations can be effective in treating and / or preventing such medical conditions as cerebral ischemia-induced hypoglycemia, hypoglycemic brain damage caused, for example, by congenital hyperinsulinism in children, and / or other conditions that severely reduce blood glucose levels. Alternatively, regulation of blood glucose concentrations can be effective in counteracting the effects of injections of excessive amounts of insulin, or inadequate nutritional or vitamin intake (e.g., deficiency of vitamin B3 (niacin, derived from nicotinic acid and nicotinamide)) can result in pellagra, a classical niacin deficiency disease characterized by bilateral dermatitis, diarrhea, and dementia.
[0065] Additionally, regulation of blood glucose concentrations can be effective in treating and / or preventing hypoglycemia, hyperglycemia, impaired glucose tolerance, impaired fasting glucose, and type 1 and type 2 diabetes.
[0066] Modulation of blood glucose levels by the methods described herein may also be advantageous in counteracting the effects of blood glucose lowering drugs such as acetaminophen, alcohol, anabolic steroids, clofibrate, disopyramide, gemfibrozil, monoamine oxidase inhibitors (MAOIs), pentamidine or sulfonylureas (such as glipizide, glyburide and glimepiride).
[0067] Other conditions with plausible implications to NAD biosynthesis, such as dementia, may also be beneficially treated and / or prevented by regulating blood glucose. See, e.g., Guest et al., "Changes in Oxidative Damage, Inflammation and [NAD(H)] with Age in Cerebrospinal Fluid," PLOS 1. January 2014, Vol. 9(1):e85335.
[0068] The increase, decrease and / or maintenance of blood glucose concentration can be quantified, for example, by a percentage above, below or between one or more previously determined levels, or can be quantified by a particular blood glucose concentration or range thereof.
[0069] For example, the blood glucose concentration can be increased by at least about 5% above the previously determined level, at least about 10% above the previously determined level, at least about 25% above the previously determined level; at least about 50% above the previously determined level, at least about 75% above the previously determined level, at least about 100% above the previously determined level, at least about 150% above the previously determined level, or at least about 200% above the previously determined level. As another example, the blood glucose concentration can be increased by at least about 5% below the previously determined level, at least about 10% below the previously determined level, at least about 25% below the previously determined level, at least about 50% below the previously determined level, at least about 75% below the previously determined level, at least about 100% below the previously determined level, at least about 150% below the previously determined level, or at least about 200% below the previously determined level. As yet another example, blood glucose concentrations can be maintained (e.g., with a series of increases and / or decreases, or without decreases and / or decreases) at a concentration that is about 50% or less, e.g., about 40% or less, about 30% or less, about 20% or less, about 10% or less, about 5% or less, of an already determined level.
[0070] Alternatively, the blood glucose concentration can be maintained at, above, or below a particular blood glucose concentration, or within a desired range of blood glucose concentrations (e.g., by a series of increases and / or decreases, or without decreases and / or decreases). For example, the blood glucose concentration can be maintained at a concentration of more than about 60 mg / dL, more than about 70 mg / dL, more than about 100 mg / dL, more than about 110 mg / dL, or more than about 125 mg / dL. Alternatively, the blood glucose concentration can be maintained at a concentration of less than about 200 mg / dL, less than about 175 mg / dL, less than about 150 mg / dL, less than about 125 mg / dL, less than about 110 mg / dL, or less than about 100 mg / dL. As another example, blood glucose concentration can be maintained at a concentration of about 60 mg / dL to about 140 mg / dL, about 90 mg / dL to about 130 mg / dL, about 100 mg / dL to about 125 mg / dL, or about 110 mg / dL to about 125 mg / dL.
[0071] Drug toxicity In some embodiments, the present invention relates to the use of NMN to prevent side effects and protect cells from toxicity. Toxicity can be the side effects of irradiation or exogenous chemicals on the body's cells. Examples of toxins are medicines, drugs of abuse, and irradiation such as UV or X-ray light. Both radiation toxicity and chemical toxicity have the potential to damage biological molecules such as DNA. This damage usually occurs indirectly through chemical reactions of exogenous agents or their metabolic products by biological molecules, or by stimulating the production of reactive oxygen species (e.g., superoxide, peroxide, hydroxyl radical). Repair systems in cells eliminate and repair the damage caused by the toxins.
[0072] Enzymes that use NAD+ play a role in DNA repair processes. For example, DNA repair syndromes include, but are not limited to, Cockayne syndrome. Specifically, poly(ADP-ribose) polymerase (PARP), particularly PARP-1, is activated by DNA strand breaks and affects DNA repair. PARP consumes NAD+ as an adenosine diphosphate ribose (ADPR) donor to synthesize poly(ADP-ribose) on nuclear proteins such as histones and PARP itself. PARP activity promotes DNA repair, but overactivation of PARP can cause severe depletion of cellular NAD+, leading to cell necrosis. The apparent sensitivity of NAD+ metabolism to genotoxicity has provided pharmacological insight into the inhibition of PARP as a means to improve cell survival. Numerous reports have shown that PARP inhibition increases NAD+ concentrations in cells subjected to genotoxicity, resulting in reduced cell necrosis. See, for example, Fang et al., Defective Mitophagy in XPA via PARP-1 Hyperactivation and NAD+ / SIRT1 Reduction. Cell 2014, 157:882-896. Nevertheless, cell death due to toxicity still occurs, presumably because cells are able to complete the apoptotic pathways activated by genotoxicity. Thus, even with PARP inhibition, a significant number of cell deaths still occur as a result of DNA / macromolecular damage. This result suggests that while improving NAD+ metabolism in genotoxicity may be partially effective in improving cell survival, other proteins that modulate apoptosis sensitivity, such as sirtuins, may also play an important role in the cellular response to genotoxicity.
[0073] The physiological and biochemical mechanisms that determine the effects of chemical and radiotoxicity in tissues are complex, and evidence indicates that NAD+ metabolism is a key aspect of the cellular stress response pathway. For example, upregulation of NAD+ metabolism by nicotinamide / nicotinic acid mononucleotide (NMNAT) overexpression has been shown to protect against neuronal axonal degeneration, and pharmacologically used nicotinamide has recently been shown to provide neuroprotection in models of fetal alcohol syndrome and fetal ischemia. Such protective effects may be due to upregulated NAD+ biosynthesis, which increases the pool of available NAD+ that is subject to depletion during genotoxic stress. This depletion of NAD+ is mediated by PARP enzymes, which are activated by DNA damage and can deplete cells of NAD+, leading to necrosis. Another mechanism of enhanced cytoprotection that can act in concert with upregulated NAD+ biosynthesis is the activation of cytoprotective transcriptional programs regulated by sirtuin enzymes.
[0074] Aging / Stress In certain embodiments, the present invention provides methods for extending cell lifespan, extending cell proliferation capacity, slowing down cell aging, promoting cell survival, delaying cellular senescence in cells, mimicking the effects of caloric restriction, increasing cell resistance to stress, or preventing cell apoptosis by contacting cells with NMN and / or NAD+. Recent studies have demonstrated that NAD+ plays a role in the aging process and in age-related diseases and conditions. See, for example, Imai et al., "NAD+ and sirtuins in aging and disease," Trends in Cell Biol. 2014, 24(8):464-471; and Gomes et al., "Declining NAD+ Induces a Pseudohypoxic State Disrupting Nuclear-Mitochondrial Communication during Aging," Cell 2013, 155:1624-1638.
[0075] The methods described herein can be used to increase the amount of time that cells, particularly primary cells (e.g., cells obtained from an organism, such as a human), can remain viable in ex vivo cell culture. Embryonic stem (ES) cells and pluripotent cells, as well as cells differentiated therefrom, can also be treated with nicotinamide mononucleotide-based or derivative compounds to maintain the cells or their progeny in culture for longer periods of time. Such cells can also be used, for example, for transplantation into a subject after ex vivo modification.
[0076] In certain embodiments, cells that are intended to be preserved for long periods of time can be treated with NMN and / or NAD+. The cells can be in suspension (e.g., blood cells, serum, biological growth medium, etc.) or in tissues or organs in a subject. For example, blood collected from an individual for transfusion purposes can be treated with NMN and / or NAD+ to preserve the blood cells for longer periods of time. Additionally, blood that is to be used for forensic purposes can also be preserved using NMN and / or NAD+. Other cells that can be treated to extend their lifespan or protect them from apoptosis include consumable cells, such as cells derived from non-human mammals (such as meat) or plant cells (such as vegetables).
[0077] NMN and / or NAD+ can also be applied during development and growth periods in mammals, plants, insects, or microorganisms, for example, to alter, inhibit, or accelerate developmental and / or growth processes.
[0078] In certain embodiments, NMN and / or NAD+ can be used to treat cells useful for transplantation or cell therapy, including, for example, solid tissue grafts, organ transplants, cell suspensions, stem cells, bone marrow cells, and the like. The cells or tissue can be an autograft, an allograft, a syngeneic graft, or a xenograft. The cells or tissue can be treated with NMN and / or NAD+ prior to administration / implantation into the subject, simultaneously with administration / implantation, and / or after administration / implantation. The cells or tissue can be treated prior to removal of the cells from the donor individual, after removal of the cells or tissue from the donor individual ex vivo, or after implantation into the recipient. For example, the donor or recipient individual may be treated systemically with NMN and / or NAD+, or a portion of the cells / tissue may be treated locally with NMN and / or NAD+. In certain embodiments, the cells or tissue (or the donor / recipient individual) may be further treated with another therapeutic agent useful for prolonging the survival of the graft, such as, for example, an immunosuppressant, a cytokine, an angiogenic factor, etc.
[0079] In certain embodiments, cells can be treated with an amount of NMN that increases the level of NAD+ in vivo, for example to increase their life span or prevent apoptosis. For example, skin can be protected from aging (wrinkling, loss of elasticity, etc.) by treating skin or epithelial cells with an amount of NMN that increases the level of intracellular NAD+. In an exemplary embodiment, skin is contacted with a pharmaceutical or cosmetic composition that includes an amount of NMN that increases the level of intracellular NAD+. Exemplary skin disorders or skin conditions that can be treated by the methods described herein include disorders or diseases associated with or caused by inflammation, sun damage, or natural aging. For example, the compositions are utilized to prevent or treat contact dermatitis (including irritant contact dermatitis and allergic contact dermatitis), atopic dermatitis (also known as allergic eczema), actinic keratosis, keratosis disorders (including eczema), epidermolysis bullosa (including pemphigus), exfoliative dermatitis, seborrheic dermatitis, erythema (including erythema multiforme and erythema nodosum), damage caused by the sun or other light sources, discoid lupus erythematosus, dermatomyositis, psoriasis, skin cancer, and the effects of natural aging. In other embodiments, an amount of NMN that increases intracellular NAD+ levels can be used to treat and promote healing of wounds and / or burns, including, for example, first, second, or third degree burns and / or thermal, chemical, or electrical burns. The formulations may be administered topically to the skin or mucosal tissue as an ointment, lotion, cream, microemulsion, gel, solution, or the like, as further described herein, within the context of a dosing regimen effective to produce the desired result.
[0080] Topical formulations containing NMN in an amount that increases intracellular NAD+ levels can also be used as preventative compositions, such as chemopreventive compositions. When used in chemopreventive methods, sensitive skin is treated before any visible condition occurs in a particular individual.
[0081] In certain embodiments, the amount of NMN that increases the level of intracellular NAD+ can be used to treat or prevent diseases or conditions in a subject that are caused or aggravated by cellular senescence, such as a method for reducing the aging rate of a subject after aging has occurred, a method for extending the lifespan of a subject, a method for treating or preventing diseases or conditions related to lifespan, a method for treating or preventing diseases or conditions related to the proliferation capacity of cells, and a method for treating or preventing diseases or conditions that result from cell damage or death.In certain embodiments, the method does not act by reducing the incidence of diseases that shorten the lifespan of a subject.In certain embodiments, the method does not act by reducing the mortality rate caused by diseases such as cancer.
[0082] In certain embodiments, an amount of NMN that increases intracellular NAD+ levels can be administered to a subject to generally increase the lifespan of the subject's cells and protect them from stress and / or apoptosis. Treating a subject with NMN can be similar to hormesis, i.e., subjecting the subject to mild stress that is beneficial to the organism, and can extend their lifespan.
[0083] NMN can also be administered to subjects in an amount that increases the level of intracellular NAD+ to protect cells from cell death and treat diseases, such as chronic diseases associated with cell death.Exemplary diseases include neuronal cell death, neuronal dysfunction, or muscle cell death or dysfunction, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, and muscular dystrophy; AIDS; fulminant hepatitis; diseases linked to brain degeneration, such as Creutzfeldt-Jakob disease, retinitis pigmentosa, and cerebellar degeneration; bone marrow dysplasia, such as aplastic anemia; ischemic diseases, such as myocardial infarction and stroke; liver diseases, such as alcoholic hepatitis, hepatitis B, and hepatitis C; joint diseases, such as osteoarthritis; atherosclerosis; hair loss; UV light damage to the skin; lichen planus; skin atrophy; cataract; and graft rejection.Cell death can also be caused by surgery, drug treatment, chemical exposure, or radiation exposure.
[0084] An amount of NMN that increases the level of intracellular NAD+ can also be administered to subjects suffering from acute diseases, such as organ or tissue damage, such as subjects suffering from stroke or myocardial infarction, or subjects suffering from spinal cord injury.An amount of NMN that increases the level of intracellular NAD+ can also be used to repair alcoholic liver.
[0085] cardiovascular disease In certain embodiments, the present invention provides methods for treating and / or preventing cardiovascular disease by administering to a subject in need thereof an amount of NMN that increases the level of intracellular NAD+. The benefits of NAD+ in treating cardiovascular disease have been described in several studies, such as Borradaile et al., "NAD+, Sirtuins, and Cardiovascular Disease," Current Pharmaceutical Design 2016, vol. 15(1):110-117.
[0086] Cardiovascular diseases that can be treated or prevented by an amount of NMN that increases the level of intracellular NAD+ include idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive heart disease, as well as myocarditis.Similarly, atherosclerosis (macrovascular disease) of major blood vessels such as the aorta, coronary artery, carotid artery, cerebrovascular artery, renal artery, iliac artery, femoral artery, and popliteal artery can be treated or prevented using the compounds and methods described herein.Other vascular diseases that can be treated or prevented include those related to platelet aggregation, retinal arterioles, glomerular arterioles, vasa nervorum, cardiac arterioles, associated capillary beds of the eye, kidneys, heart, and central and peripheral nervous systems.
[0087] Yet other disorders that can be treated with an amount of NMN that increases the level of intracellular NAD+ include restenosis, such as restenosis after coronary intervention, and disorders associated with abnormal levels of high and low density cholesterol. Another disease that can benefit from NAD+ treatment is nonalcoholic steatohepatitis (NASH), a fatty liver disease.
[0088] Circadian rhythm The circadian clock is encoded by a transcription-translation feedback loop that synchronizes behavior and metabolism with the light-dark cycle. It was unexpectedly discovered that both nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in mammalian NAD+ biosynthesis, and NAD+ levels exhibit circadian oscillations regulated by the core clock machinery in mice. Inhibiting NAMPT promotes oscillations of the clock gene Per2 by releasing CLOCK:BMAL1 from repression by SIRT1. In turn, the circadian transcription factor CLOCK binds and upregulates Nampt, thus modulating the NAMPT / NAD + and completes a feedback loop involving SIRT1 / CLOCK:BMAL1. See, e.g., Ramsey et al., "Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis," Science 2009, 324:651-654.
[0089] Thus, the cyclical variation in NAMPT-mediated NAD+ biosynthesis suggests that it affects physiological cycles and possibly sleep-wake and hunger-feeding cycles. Without being bound to a single principle, NAD+ is thought to act as an important "metabolic oscillator" for cyclical regulation of responses to environmental cues through control of SIRT1 activity. The compounds disclosed herein can be used to affect the circadian feedback loop through NAMPT-mediated NAD+ biosynthesis and / or the pathways underlying the temporal linkage of metabolic, physiological and circadian cycles in mammals.
[0090] NAMPT / NAD + -Recognition of a regulatory pathway involving SIRT1 / CLOCK:BMAL1 has broad implications for understanding how physiological and behavioral cycles are coordinated with the environmental light-dark cycle. For example, during sleep, when animals are normally inactive and fasting, NAMPT levels steadily increase, reaching a peak at the beginning of the wakefulness period, coinciding with feeding. As a result of the increase in NAMPT, NAD + is elevated and stimulates SIRT1, which orchestrates appropriate metabolic responses in the liver, including a switch from catabolic to anabolic pathways.
[0091] In certain embodiments, the invention provides methods of modulating a mammal's core clock mechanism (sometimes referred to as the circadian clock), thereby affecting behaviors, activities, and / or biological functions that occur in or are influenced by circadian or daily cycles and that are at least in part regulated by the circadian clock. Generally, the methods include administering to a patient or mammal in need of circadian clock modulation a therapeutic or prophylactic amount of a circadian clock-regulating compound.
[0092] The methods of treatment disclosed herein are generally directed to methods of modulating the circadian clock, thereby regulating or affecting biological functions that are modulated by (sometimes also referred to as being influenced by, coordinated with, or mediated by) circadian clock activity. Typically, these biological functions exhibit repeating patterns of activity and inactivity approximately every 24 hours, i.e., oscillations between "active" and "inactive" states during a 24-hour period.
[0093] Thus, the present invention provides a method for regulating the activity of the circadian clock by administering a circadian clock-regulating compound to a mammal in need thereof. In general, the regulation of the activity of the circadian clock is the result of the regulation of CLOCK:BMAL1, which is achieved by the present method by regulating the activity of SIRT1. The activity of SIRT1 is generally regulated by the present invention by administering a circadian clock-regulating compound, and in certain embodiments, by administering an amount of NMN that affects the NAD+ pathway. The regulation of the circadian clock thereby allows the regulation of the activity mediated by the circadian clock.
[0094] According to the present invention, the activity of the circadian clock can be increased, decreased or maintained by administration of a circadian clock-regulating compound. Thus, the biological functions (sometimes also referred to as biological activities) regulated by the activity of the circadian clock can also be increased, decreased or maintained. Furthermore, these biological functions can be time-shifted. That is, an activity that normally occurs during a certain period, such as, for example, daytime or daytime (sometimes also referred to as light cycle), or nighttime or nighttime (sometimes also referred to as dark cycle), can be shifted so that this activity occurs instead during the dark cycle or light cycle, respectively.
[0095] Any of several biological functions that are normally affected by the activity of the circadian clock can be regulated by the method of the present invention. Thus, the method can be used, for example, to treat disorders or disease states that are the result of irregular, improper, or pathological function of the circadian clock. Similarly, the method can be used to treat disorders or conditions caused by external factors that affect the proper function or activity of the circadian clock or require the clock to be "reset." For example, administration of a circadian clock-regulating compound to a patient experiencing a metabolic disorder can provide therapeutic benefit not only when the patient's serum NMN or NAD levels are elevated, but also when the patient observes improvements in other disorders involving metabolic disorders, such as weight loss or weight gain. In some treatment regimes, the circadian clock-regulating compound of the present invention can be administered to a patient at risk of developing a disorder described herein or to a patient reporting one or more physiological symptoms of such a disorder, even when a diagnosis of a metabolic disorder may not have been made.
[0096] Examples of disorders, disease states or conditions that can be treated by the methods of the present invention include, but are not limited to, travel to or through one or more time zones, a change in work shift, a night work shift, or a change in the physical condition of a mammal caused, for example, by pregnancy, or the administration of any type of drug. Thus, the methods of the present invention can be used to treat or prevent disorders, symptoms of disorders, or symptoms caused by external factors. Such disorders and conditions can include, for example, metabolic disorders such as improper cycling or timing of feeding and fasting cycles, hyperglycemia, hypoglycemia, or diabetes; sleep disorders such as insomnia, advanced sleep phase syndrome, delayed sleep phase syndrome, sleep / wake cycle mismatch, or narcolepsy, or improved wakefulness in individuals suffering from excessive sleepiness; and symptoms caused by external factors such as travel to or through one or more time zones (jet lag), a shift in or out of daylight saving time, a change in work shift or night work shift, pregnancy, or a medication taken for an unrelated disease or disorder.
[0097] Thus, in certain embodiments, the present invention is directed to a method of regulating a biological function in a mammal, the function being influenced by the circadian clock. The method comprises administering to the mammal a therapeutic or prophylactic amount (sometimes also referred to as a circadian clock-regulating amount) of a circadian clock-regulating compound. The biological function can be, for example, any one of the biological functions described herein. In certain embodiments, the present invention comprises a method of treating a metabolic disorder in a mammal, comprising administering to the mammal a therapeutic or prophylactic amount of a circadian clock-regulating compound. In other embodiments, the present invention comprises a method of treating a disorder in a mammal mediated by circadian clock function, comprising administering to the mammal a therapeutic or prophylactic amount of a circadian clock-regulating compound. According to any one of these embodiments, the circadian clock-regulating compound can be, for example, nicotinamide, nicotinamide mononucleotide (NMN), nicotinamide adenine dinucleotide (NAD), salts and prodrugs thereof, nicotinamide phosphoribosyltransferase (NAMPT), and combinations thereof, as described in more detail below. In other embodiments, the circadian clock-regulating compound can be an antagonist of any one of the compounds listed above, which can seek to oppose the effects of nicotinamide, nicotinamide mononucleotide (NMN), nicotinamide adenine dinucleotide (NAD), salts and prodrugs thereof, nicotinamide phosphoribosyltransferase (NAMPT), and combinations thereof.
[0098] In certain embodiments, the present invention is directed to a method of regulating metabolic activity in a mammal, comprising administering a therapeutic amount of a circadian clock-regulating compound to the mammal. In certain embodiments, the metabolic activity of the mammal is increased. In other embodiments, the metabolic activity is decreased. In still other embodiments, the metabolic activity of the mammal is maintained at a desired level, thereby preventing activity / inactivity fluctuations. In still other embodiments, the metabolic activity is caused to occur in the light cycle (as opposed to normally occurring in the dark cycle). In other embodiments, the metabolic activity is caused to occur in the dark cycle (as opposed to normally occurring in the light cycle). In certain embodiments, the circadian clock-regulating compound is administered to the mammal to increase anabolic activity of the liver (e.g., increase the activity of a metabolic pathway in the liver, or shift or switch the activity of the liver from catabolism to anabolism). In other embodiments, the circadian clock-regulating compound is administered to the mammal to increase catabolic activity of the liver (e.g., decrease the activity of a metabolic process).
[0099] Mitochondrial Disease and Metabolism In addition to regulating circadian rhythm and protecting neuronal cells from cell death, sirtuins such as SIRT3, SIRT4 and SIRT5 are found in mitochondria.SIRT3 is expressed at high levels in metabolically active tissues.The modulation of SIRT3 has various physiological applications for muscle cells, including mimicking calorie restriction or exercise, increasing mitochondrial biogenesis or metabolism, sensitizing cells to glucose uptake, increasing fatty acid oxidation, and reducing reactive oxygen species.In addition, it has been demonstrated herein that SIRT3 is involved in promoting cell survival during genotoxic stress.Therefore, the modulation of SIRT3 levels is also applied to mediate cell survival.
[0100] Increasing the protein or activity level of SIRT3 in muscle cells can mimic the benefits of calorie restriction or exercise. In some embodiments, the present invention relates to a method for enhancing mitochondrial biogenesis or metabolism, or a method for enhancing mitochondrial activity / endurance in muscle cells by contacting the muscle cells with an IS agent that increases the protein or activity level of SIRT3 in the cells. In some embodiments, the present invention relates to a method for sensitizing glucose uptake in muscle cells by contacting the muscle cells with an agent that increases the protein or activity level of SIRT3 in the cells. In further embodiments of the present invention, a method for increasing fatty acid oxidation in muscle cells by contacting the muscle cells with an agent that increases the protein or activity level of SIRT3 in the cells. Some embodiments of the present invention relate to a method for reducing reactive oxygen species (ROS) in muscle cells by contacting the muscle cells with an agent that increases the protein or activity level of SIRT3 in the cells.
[0101] Elevating the level of SIRT3 benefits many diseases and disorders that are affected by metabolism in mitochondria.Elevating SIRT3 can be useful in any subject that requires metabolic activation of one or more of its muscles, for example smooth muscle or cardiac muscle or their muscle cells.Subject can be the subject with cachexia or muscle wasting.
[0102] Increasing SIRT3 can also be used to increase or maintain body temperature, for example in a hypothermic subject. Alternatively, inhibiting SIRT3 can be used to decrease body temperature, for example in a subject with fever or hyperthermia.
[0103] In general, activation of SIRT3 can be used to stimulate metabolism of any type of muscle, such as the intestines or muscles of the digestive system, or the urinary tract, and thus can be used to control intestinal motility, e.g., constipation and incontinence.
[0104] Other embodiments in which increasing SIRT3 may be useful include muscle repair, such as after surgery or accident, increasing muscle mass, and increasing athletic performance.
[0105] Thus, the present invention provides methods in which beneficial effects occur by contacting one or more muscle cells with an amount of NMN that increases the protein or activity level of SIRT3 in the cells. These methods effectively promote, increase, or stimulate one or more of the following: mimicking the benefits of caloric restriction or exercise in muscle cells, increasing mitochondrial biogenesis or metabolism, increasing mitochondrial activity and / or resistance in muscle cells, sensitizing glucose uptake in muscle cells, increasing fatty acid oxidation in muscle cells, reducing reactive oxygen species (ROS) in muscle cells, increasing expression of PGC-la and / or ucp3 and / or GLUT4 in muscle cells, and AMP-activated protein kinase (AMPK) activation in muscle cells.
[0106] Various types of muscle cells can be contacted by the present invention. In some embodiments, the muscle cells are skeletal muscle cells. In certain embodiments, the muscle cells are slow-twitch muscle cells, such as soleus muscle cells. In some embodiments, the methods of the present invention include administering to a subject in need of such treatment an amount of NMN that increases SIRT3 protein or activity levels in the subject's cells.
[0107] The cell contacted or the subject treated with the above method is preferably a cell in need of an increase in SIRT3 in protein or activity levels. In certain embodiments, the cell is a cell of a subject with a disease.
[0108] Also provided are methods of regulating skeletal muscle metabolism or skeletal muscle energy homeostasis in a subject, in which an agent that modulates SIRT3 protein or activity levels in the subject, i.e., a SIRT3 modulator as described herein, is administered to a subject in need thereof.
[0109] Also provided is a method for increasing the protein level of SIRT3 in muscle cells or muscles of a subject. Such a method includes subjecting cells or a subject to calorie restriction or fasting, or administering to a subject in need thereof an amount of NMN that increases the protein or activity level of SIRT3 in muscle cells. Diseases, disorders and conditions for which such methods are useful include mitochondrial disease, metabolic disorders, neurological disorders, muscular disorders, cardiovascular diseases and overweight or obesity. Particular metabolic disorders, diseases or conditions include insulin resistance, diabetes, diabetes-related conditions or disorders, or metabolic syndrome. Other metabolic disorders will be known to those skilled in the art.
[0110] Mitochondrial diseases that can be treated include diseases that show various symptoms caused by mitochondrial dysfunction in cells. Mitochondrial diseases can be classified in various ways according to the type of biochemical abnormality, clinical symptoms, or DNA abnormality. Types named KSS (chronic progressive external ophthalmoplegia), MERRF (myoclonus epilepsy with ragged red fibers, Fukuhara syndrome), MELAS, Leber's disease, Leigh encephalopathy, and Pearson's disease are widely known. Among them, MELAS is a type that mainly shows stroke-like episodes, and is considered to be the most frequent type in mitochondrial diseases, accounting for more than 30% of the total.
[0111] In certain embodiments, NMN is useful for treating diseases or disorders associated with DNA repair disorders or mitochondrial dysfunction (e.g., due to deregulation of mitochondrial homeostasis). In some embodiments, "mitochondrial dysfunction" or "deregulation of mitochondrial homeostasis" refers to one or more mitochondrial components (e.g., ETC components) being depleted, for example, by reduced mitochondrial gene expression or mitochondrial DNA content, resulting in impaired mitochondrial function (e.g., loss or reduction of oxidative phosphorylation (OXPHOS) capacity). Examples of DNA repair disorders include Cockayne syndrome and TTD.
[0112] Retinal Diseases and Disorders Photoreceptor neuronal cell death and vision can be rescued by NMN administration. In certain embodiments, nicotinamide phosphoribosyltransferase (NAMPT)-mediated NAD biosynthesis can play a role in rod and / or cone PR neuron survival. In certain embodiments, reduced NAD levels can cause impaired mitochondrial function and altered TCA cycle metabolites in PR neurons, leading to cell death and blindness.
[0113] Lack of NAMPT can lead to the death of photoreceptors, loss of normal retinal structure and function, and loss of vision.In some cases, damage to photoreceptor neurons and their functions can be reversed by supplementation with NMN, which is the product of NAMPT enzyme reaction.Disclosed herein is a method of administering NMN to restore NAD levels in the retina.In some embodiments, supplementation with NMN can be an effective therapeutic intervention for many retinal degenerative diseases.
[0114] Provided herein is a method for treating, preventing and reducing the risk of diseases associated with photoreceptor dysfunction, including but not limited to age-related macular degeneration (AMD), hereditary and acquired retinal diseases, including but not limited to retinitis pigmentosa (RP), rod and cone dystrophism and Leber's congenital amaurosis (LCA), by administering NMN to a subject. In certain embodiments, NMN administration can be an effective intervention for the prevention and / or treatment of orphan retinal degenerative diseases, including but not limited to rod dystrophies, cone dystrophies, retinitis pigmentosa, other hereditary retinal degenerations, Leber's congenital amaurosis (LCA) and acquired retinal degenerations, including but not limited to age-related macular degeneration, degeneration of photoreceptors following retinal detachment.
[0115] In some embodiments, these methods can include administering to a subject a pharma- tically effective amount of nicotinamide mononucleotide (NMN). In some embodiments, the pharma- tically effective amount of nicotinamide mononucleotide (NMN) can be an amount effective to increase retinal NAD levels.
[0116] Disclosed herein is a method for treating macular degeneration in a subject. In some embodiments, the method comprises treating abnormalities in retinal NAD levels, including abnormally low retinal NAD levels, in a subject. These methods comprise administering NMN to the subject. In some embodiments, the method comprises treating retinal degeneration in a subject. In some embodiments, the method comprises treating photoreceptor damage in a subject. In some embodiments, the method comprises treating photoreceptor degeneration in a subject.
[0117] In some embodiments, the method comprises treating the vision loss associated with retinal degeneration in a subject.In some embodiments, the method comprises treating the abnormality of retinal structure in a subject.In some embodiments, the method comprises increasing the NAD level of the retina in a subject.
[0118] In some embodiments, the method comprises reducing the risk of developing macular degeneration in a subject. In some embodiments, the method comprises reducing the risk of developing abnormality in retinal NAD levels in a subject. In some embodiments, the method comprises reducing the risk of developing retinal degeneration in a subject. In some embodiments, the method comprises reducing the risk of developing photoreceptor damage / degeneration in a subject. In some embodiments, the method comprises reducing the risk of developing vision loss associated with retinal degeneration in a subject. In some embodiments, the method comprises reducing the risk of developing abnormality in retinal structure in a subject.
[0119] In some embodiments, the method includes treating a retinal disease in a subject. In some embodiments, the retinal disease that can be treated by administering NMN can be retinitis pigmentosa (RP), Leber's congenital amaurosis (LCA), rod dystrophy, cone dystrophy, rod-cone dystrophy, cone-rod dystrophy, age-related macular degeneration, degeneration of photoreceptors after retinal detachment, or a combination thereof.
[0120] In certain embodiments, β-nicotinamide mononucleotide (NMN) crystal forms (and formulations made using such crystal forms) may be used to treat, ameliorate, mitigate, slow, halt, prevent, or reverse age-related obesity in a subject. In some embodiments, the invention relates to methods of treating, ameliorating, mitigate, slow, halt, prevent, or reverse age-related increases in blood lipid levels in a subject. In some embodiments, the invention relates to methods of treating, ameliorating, mitigate, slow, halt, prevent, or reverse age-related decline in insulin sensitivity in a subject. In some embodiments, the invention relates to methods of treating, ameliorating, mitigate, slow, halt, prevent, or reverse age-related impairment of memory function in a subject. In some embodiments, the invention relates to methods of treating, ameliorating, mitigate, slow, halt, prevent, or reverse age-related decline in ocular function in a subject. In some embodiments, the invention relates to methods of treating, ameliorating, mitigate, slow, halt, prevent, or reverse age-related retinal degeneration in a subject. In some embodiments, the invention relates to methods of treating, ameliorating, mitigate, slow, halt, prevent, or reverse dry eye. In some embodiments, the present invention relates to methods of treating, ameliorating, alleviating, slowing, halting, preventing, or reversing age-related dry eye.In some embodiments, the present invention relates to methods of treating, ameliorating, alleviating, slowing, halting, preventing, or reversing infertility in a subject.
[0121] In some embodiments, the present invention provides a method of treating age-related impairment in neural stem / progenitor cell (NSPC) functionality in a subject through administration of a crystalline form of NMN or a formulation produced using such a crystalline form. In some embodiments, the present invention provides a method of reducing age-related decline in NSPC populations in a subject through administration of a crystalline form of NMN or a formulation produced using such a crystalline form. In some embodiments, the present invention provides a method of preserving at least one NSPC in a subject through administration of a crystalline form of NMN or a formulation produced using such a crystalline form. In some embodiments, the present invention provides a method of enhancing NAD biosynthesis in a subject through administration of a crystalline form of NMN or a formulation produced using such a crystalline form. In some embodiments, the present invention provides a method of promoting NSPC proliferation in a subject comprising administering to the subject a crystalline form of NMN or a formulation produced using such a crystalline form. The method of each of these embodiments can comprise, consist essentially of, or consist of administration of a therapeutically effective amount of a crystalline form of NMN or a formulation produced using such a crystalline form.
[0122] In some embodiments, the present invention provides a method of increasing bone density levels in a subject. In some embodiments, the present invention provides a method of treating abnormally low bone density levels in a subject. In some embodiments, the present invention provides a method of treating age-related bone density loss in a subject. In some embodiments, the present invention provides a method of treating osteoporosis in a subject. In some embodiments, the present invention provides a method of preventing age-related bone density loss in a subject. The method of each of these embodiments can comprise, consist essentially of, or consist of administering a therapeutically effective amount of a crystalline form of NMN or a formulation made using such a crystalline form.
[0123] In certain embodiments, the present invention relates to methods of preventing, reducing the risk of, and treating various diseases associated with photoreceptor dysfunction, including but not limited to age-related macular degeneration (AMD), inherited and acquired retinal diseases, such as but not limited to retinitis pigmentosa (RP), rod and cone dystrophy, and Leber's congenital amaurosis (LCA), by administration of NMN. In various embodiments, administration of NMN crystal forms or formulations made using such crystal forms can be an effective intervention for the prevention and / or treatment of orphan retinal degenerative diseases, including but not limited to rod dystrophies, cone dystrophies, retinitis pigmentosa, other inherited retinal degenerations, Leber's congenital amaurosis (LCA), and acquired retinal degenerations, such as but not limited to age-related macular degeneration, degeneration of photoreceptors following retinal detachment. In various embodiments, crystalline forms of NMN or formulations made using such crystalline forms can be administered by any route of administration known to those of skill in the art, including but not limited to oral, parenteral, intraocular, intraperitoneal, intravenous, or intramuscular. In various embodiments, NMN can be administered with or without excipients.
[0124] In some embodiments, NMN treats age-related diseases. In certain embodiments, the age-related diseases are Alzheimer's disease, amniotropic lateral sclerosis, arthritis, atherosclerosis, cachexia, cancer, cardiac hypertrophy, heart failure, cardiac hypertrophy, cardiovascular disease, cataracts, colitis, chronic obstructive pulmonary disease, dementia, diabetes, frailty, heart disease, steatohepatitis, high blood cholesterol, high blood pressure, Huntington's disease, hyperglycemia, hypertension, infertility, inflammatory bowel disease, insulin resistance disorder, lethargy, metabolic syndrome, muscular dystrophy, multiple sclerosis, neuropathy, kidney disorder, obesity, osteoporosis, Parkinson's disease, psoriasis, sarcopenia, sleep disorder, sepsis, and / or stroke. In some embodiments, the mitochondrial disease is mitochondrial myopathy, diabetes mellitus and deafness (DAD), Leber's hereditary optic neuropathy (LHON), Leigh's syndrome, neuropathy, ataxia, retinitis pigmentosa and petosis (NARP), myoclonus epilepsy with ragged-red fibers (MERRF), myoneurogenic gastrointestinal encephalopathy (MNGIE), mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like symptom (MELAS), Kearns-Sayre syndrome (KSS), chronic progressive external ophthalmoplegia (CPEO), and / or mtDNA depletion.
[0125] Examples of diseases, disorders, or conditions associated with mitochondrial dysfunction include, but are not limited to, aging, age-related diseases, mitochondrial diseases (e.g., Alpers' disease, Barth's syndrome, beta-oxidation defects, carnitine acylcarnitine deficiency, carnitine deficiency, creatine deficiency syndrome, coenzyme Q10 deficiency, complex I deficiency, complex II deficiency, complex III deficiency, complex IV deficiency / COX deficiency, complex V deficiency, chronic progressive external ophthalmoplegia syndrome, CPT I deficiency, CPT II deficiency, Kearns-Sayre syndrome, lactic acidosis, long-chain acyl-CoA dehydrongenase deficiency, Leigh syndrome, Luft's disease, glutaric aciduria type II, mitochondrial cytopathy, mitochondrial DNA depletion, mitochondrial encephalopathy, mitochondrial myopathy and Parkinsonism), metabolic diseases and disorders (e.g., amino acid deficiencies), diseases due to mitochondrial and energy deficiencies, lethargy, heart disease, cardiovascular disease, stroke, infarction, pulmonary hypertension, ischemia, cachexia, sarcopenia, neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease), dementia, lipodystrophy, fatty liver, hepatitis, cirrhosis, renal failure, pre-eclampsia, male infertility, obesity, diabetes (e.g., type I diabetes), myopathies, and muscle wasting.
[0126] In some embodiments, NMN is useful for promoting cell survival (in various species), vascular remodeling, wound healing, and general healing (e.g., treatment of wounds due to cuts, abrasions, surgery, physical injuries, trauma, burns, abrasions, sunburn, etc.). In some embodiments, the methods or compositions are useful for promoting iron homeostasis and / or erythropoiesis. In some embodiments, the methods or compositions herein are effective for promoting successful organ and tissue transplantation or promoting recovery from organ and tissue transplantation. In some embodiments, the methods and compositions provided herein are useful for maintaining cells and organs. In some embodiments, the methods and compositions provided herein have cosmetic applications for treating conditions associated with mitochondrial dysfunction on the skin or scalp / hair, such as, for example, skin aging (e.g., loss of volume and elasticity, discoloration, melasma (senislis)), wrinkles, alopecia, and reduced hair pigmentation. In some embodiments, the agents or compositions described herein are useful in products or methods related to cosmetics, energy drinks, and / or the animal and plant industries (e.g., livestock, pets, and agricultural products).
[0127] As described herein, subjects that can be treated include eukaryotic organisms such as mammals, e.g., humans, sheep, cows, horses, pigs, dogs, cats, non-human primates, mice and rats. Cells that can be treated include, e.g., eukaryotic cells from the above subjects or plant cells, yeast cells, and prokaryotic cells, e.g., bacterial cells. For example, NMN can be administered to livestock to improve their ability to withstand farming conditions for longer.
[0128] The compound can also be used to increase life span, stress resistance, and resistance to apoptosis in plants. In certain embodiments, NMN is applied to plants, for example periodically, or to fungi. In other embodiments, plants are genetically modified to produce NMN. In other embodiments, plants and fruits are treated with NMN before harvesting and shipping to increase resistance to damage during shipping. Plant seeds can also be exposed to NMN, for example, to hold them.
[0129] NMN can also be used to increase life span, stress resistance, and resistance to apoptosis in insects. In certain embodiments, NMN is applied to useful insects, such as bees and other insects involved in plant pollination. In a preferred embodiment, NMN is applied to bees involved in honey production. In general, the methods described herein can be applied to any organism, such as eukaryotic organisms that may be commercially important. For example, it can be applied to fish (aquaculture), shrimp, pigs, and birds (e.g., chickens and poultry).
[0130] Other uses of NMN include beneficially modulating the microbiome or serving as a form of vitamin B3. As a precursor to NAD, NMN is also useful in assays for diseases and conditions affected by NAD biosynthesis, such as for use as a standard.
[0131] As used herein, a treatment that "prevents" a disorder or condition refers to a compound that reduces the occurrence or frequency of a disorder or condition in a statistical sample compared to an untreated control sample, or delays the onset or reduces the severity of one or more symptoms of a disorder or condition compared to an untreated control sample. Thus, preventing cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment compared to an untreated control sample, and / or delaying the onset of detectable cancerous growths in a treated population versus an untreated control population, for example, by a statistically and / or clinically significant amount. Preventing infection includes, for example, reducing the number of diagnoses of infection in a treated population versus an untreated control population, and / or delaying the onset of symptoms of infection in a treated population versus an untreated control population. Preventing pain includes, for example, reducing the magnitude of pain sensations experienced by subjects or delaying them in a treated population versus an untreated control population.
[0132] The term "treating" includes prophylactic and / or therapeutic treatment. The term "prophylactic or therapeutic" treatment is art-recognized and includes administration of one or more of the present compositions to a host. When administered prior to clinical signs of an unwanted condition (e.g., a disease or other unwanted condition of a host animal), the treatment is prophylactic (i.e., protects the host against developing the unwanted condition), whereas when administered after signs of an unwanted condition, the treatment is therapeutic (i.e., intended to alleviate, ameliorate, or stabilize an existing unwanted condition or its side effects).
[0133] Pharmaceutical Compositions In certain embodiments, the present invention relates to pharmaceutical compositions comprising a crystalline compound of formula (I) and one or more pharma- ceutically acceptable excipients, as well as formulations prepared using such crystalline compounds and one or more pharma- ceutically acceptable excipients. In certain embodiments, the pharmaceutical preparations may be used to treat or prevent conditions or diseases described herein. In certain embodiments, the pharmaceutical preparations have sufficiently low pyrogenic activity that they are suitable for intravenous use in human patients. In certain embodiments, the present invention also relates to preparations suitable for use in dietary supplements, veterinary medicine, and agricultural related applications.
[0134] Exemplary pharma- ceutically acceptable excipients are presented herein and include, for example, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspending aids, emulsifiers, coating agents, cyclodextrins, and / or buffers. The dosage varies depending on the condition, age, and weight of the patient, the nature and severity of the disorder to be treated or prevented, the route of administration, and the form of the drug, but generally, a daily dosage of 0.01 to 3000 mg of the compound is recommended for an adult human patient, which may be administered in a single dose or multiple doses. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form is generally that amount of the compound that produces a therapeutic effect.
[0135] The exact time of administration and / or amount of composition that will give the most effective results in terms of efficacy of treatment in a given patient will depend on the activity, pharmacokinetics and bioavailability of the particular compound, the physiological condition of the patient (age, sex, type and stage of disease, general physical condition, responsiveness to a given dosage, and type of medication), route of administration, etc. However, the above guidelines can be used as a basis to fine-tune the treatment, e.g., to determine the optimal time and / or amount of administration, which requires only routine experimentation consisting of monitoring the subject and adjusting the dosage and / or timing.
[0136] In certain embodiments, the individual to whom the composition is administered is a mammal, such as a human or a non-human mammal. When administered to an animal, such as a human, the composition or compound is preferably administered as a pharmaceutical composition, for example comprising the compound of the present invention and a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known in the art and include, for example, aqueous solutions, such as water or physiologically buffered saline, or other solvents or vehicles, such as glycols, glycerol, oils, such as olive oil, or organic esters for injection. In preferred embodiments, when such pharmaceutical compositions are for human administration, particularly invasive routes of administration (i.e., routes such as injection or implantation that avoid transport or diffusion through epithelial barriers), the aqueous solutions are pyrogen-free or substantially pyrogen-free. Excipients can be selected, for example, to provide delayed release of the agent or to selectively target one or more cells, tissues, or organs. The pharmaceutical composition can be in unit dosage form (tablets, capsules (including sprinkle capsules and gelatin capsules), granules, lyophiles for reconstitution, powders, solutions, syrups, suppositories, injectables, etc.). The composition can also be present in a transdermal delivery system, such as a skin patch. The composition can also be present in a solution suitable for topical administration, such as eye drops, via administration to the ocular mucosa.
[0137] A pharma- ceutically acceptable carrier can contain a physiologically acceptable agent that acts, for example, to stabilize, increase the solubility, or increase the absorption of a compound, such as the compound of the present invention. Such physiologically acceptable agents include, for example, carbohydrates (such as glucose, sucrose, or dextran), antioxidants (such as ascorbic acid or glutathione), chelating agents, low molecular weight proteins, or other stabilizers or excipients. The choice of a pharma- ceutical carrier that includes a physiologically acceptable agent depends, for example, on the route of administration of the composition. The preparation or pharmaceutical composition can be a self-emulsifying drug delivery system or a self-microemulsifying drug delivery system. The pharmaceutical composition (preparation) can also be a liposome or other polymer matrix, which can, for example, be incorporated with the compound of the present invention. Liposomes, which include, for example, phospholipids or other lipids, are non-toxic, physiologically acceptable, and metabolizable carriers that are relatively easy to make and administer.
[0138] The phrase "pharmacologically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment.
[0139] As used herein, the phrase "pharmaceutically acceptable carrier" refers to a pharma- ceutically acceptable substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and non-toxic to the patient. Some examples of substances that can serve as pharma- ceutically acceptable carriers include: (1) sugars (such as lactose, glucose, and sucrose), (2) starches (such as corn starch and potato starch), (3) cellulose and its derivatives (such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate), (4) powdered tragacanth, (5) malt, (6) gelatin, (7) talc, (8) excipients (such as cocoa butter and suppository wax), (9) oils (such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil), and (10) glycerol, ... (10) glycols (such as propylene glycol), (11) polyols (such as glycerin, sorbitol, mannitol, and polyethylene glycol), (12) esters (such as ethyl oleate and ethyl laurate), (13) agar, (14) buffering agents (such as magnesium hydroxide and aluminum hydroxide), (15) alginic acid, (16) pyrogen-free water, (17) isotonic saline, (18) Ringer's solution, (19) ethyl alcohol, (20) phosphate buffer, and (21) other non-toxic compatible substances used in pharmaceutical formulations. In certain embodiments, the pharmaceutical compositions of the present invention are non-pyrogenic, i.e., do not induce a significant elevation in body temperature when administered to a patient.
[0140] The term "pharmaceutically acceptable salts" refers to relatively non-toxic inorganic and organic acid addition salts of compounds. These salts can be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compounds in their free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, heptogluconate, lactobionate, laurylsulfonate, amino acid salts, and the like. The preparation of crystalline salts is detailed in the Examples below (see, for example, Berge et al. (1977) "Pharmaceutical Salts", J. Pharm. Sci., Vol. 66, pp. 1-19).
[0141] In other cases, compounds useful in the methods of the present invention contain one or more acidic functional groups and therefore can form pharma-ceutically acceptable salts with pharma-ceutically acceptable bases. The term "pharma-ceutically acceptable salts" in these instances refers to the relatively non-toxic inorganic and organic base addition salts of the compounds. These salts can also be prepared in situ during the final isolation and purification of the compounds, or by separately reacting the purified compounds in their free acid form with a suitable base of a pharma-ceutically acceptable metal cation (hydroxide, carbonate or bicarbonate), with ammonia, or with a pharma-ceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include lithium, sodium, potassium, calcium, magnesium, aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).
[0142] The pharmaceutical compositions (preparations) can be administered to a subject by any of several routes of administration, including, for example, orally (e.g., as drenches in aqueous or non-aqueous solutions or suspensions, tablets, capsules (including sprinkle capsules and gelatin capsules), boluses, powders, granules, pastes for application to the tongue), absorption through the oral mucosa (e.g., sublingually), anally, rectally, or vaginally (e.g., as pessaries, creams, or foams), parenterally (intramuscularly, intravenously, subcutaneously, or intrathecally, e.g., as a sterile solution or suspension), nasally, intraperitoneally, subcutaneously, transdermally (e.g., as a patch applied to the skin), and topically (e.g., as a cream, ointment, or spray applied to the skin, or as eye drops). The compounds are also formulated for inhalation. In certain embodiments, the compounds may simply be dissolved or suspended in sterile water. Details of suitable routes of administration and compositions suitable therefor can be found, for example, in U.S. Pat. No. 6,110,973, U.S. Pat. No. 5,763,493, U.S. Pat. No. 5,731,000, U.S. Pat. No. 5,541,231, U.S. Pat. No. 5,427,798, U.S. Pat. No. 5,358,970, and U.S. Pat. No. 4,172,896, and patents cited therein.
[0143] The preparations can be conveniently provided in unit dosage form and can be prepared by any method well known in the art of pharmacy. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form varies depending on the host treated, the particular mode of administration. The amount of active ingredient that can be combined with a carrier material to produce a single dosage form is generally the amount of compound that produces a therapeutic effect. Generally, out of 100%, this amount ranges from about 1% to about 99%, preferably from about 5% to about 70%, most preferably from about 10% to about 30% of active ingredient.
[0144] Methods of preparing these formulations or compositions include the step of bringing into association an active compound, such as a compound of the present invention, with the carriers and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately admixing a compound of the present invention with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the product.
[0145] Formulations of the present invention useful for oral administration may be in the form of capsules (including sprinkle capsules and gelatin capsules), cachets, pills, tablets, lozenges (using flavored bases, usually sucrose and acacia or tragacanth), lyophilisates, powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as a pastille (using an inert base such as gelatin and glycerin, or sucrose and acacia), and / or as a mouthwash, etc., each containing a predetermined amount of a compound of the present invention as an active ingredient. The composition or compound may also be administered as a bolus, electuary, or paste.
[0146] To prepare solid dosage forms for oral administration (capsules (including sprinkle capsules and gelatin capsules), tablets, pills, dragees, powders, granules, etc.), the active ingredient is mixed with sodium citrate or dicalcium phosphate, and / or one or more pharma- ceutically acceptable carriers, such as any of the following: (1) fillers or extenders (such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid), (2) binders (such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or acacia), (3) humectants (such as glycerol), (4) disintegrants (such as glycerol), (5) glycerol-containing gelatins (such as glycerol), (6) glycerol-containing sorbents (such as glycerol), (7) glycerol-containing sorbents (such as glycerol), (8) glycerol-containing sorbents (such as glycerol), (9) glycerol-containing sorbents (such as glycerol), (10) glycerol-containing sorbents (such as glycerol), (11) glycerol-containing sorbents (such as glycerol), (12) glycerol-containing sorbents (such as glycerol), (13) glycerol-containing sorbents (such as glycerol), (14) glycerol-containing sorbents (such as glycerol), (15) glycerol-containing sorbents (such as glycerol), (16) glycerol-containing sorbents (such as glycerol), (17) glycerol-containing sorbents (such as glycerol), (18) glycerol-containing sorbents (such as glycerol), (19) glycerol-containing sorbents (such as glycer Agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (5) solution retardants such as paraffin, (6) absorption enhancers such as quaternary ammonium compounds, (7) wetting agents such as cetyl alcohol and glycerol monostearate, (8) absorbents such as kaolin and bentonite clay, (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof, (10) complexing agents such as modified and unmodified cyclodextrins, and (11) coloring agents. In the case of capsules (including sprinkle capsules and gelatin capsules), tablets, and pills, the pharmaceutical compositions also include buffering agents. Solid compositions of this type may also be used as fillers in soft and hard-filled gelatin capsules using excipients such as lactose or milk sugar, and high molecular weight polyethylene glycols, and the like.
[0147] Tablets are made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be produced using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents or dispersants. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
[0148] Tablets and other solid dosage forms of pharmaceutical compositions, such as dragees, capsules (including sprinkle capsules and gelatin capsules), pills and granules, may be optionally scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical formulation art. They may also be formulated to release the active ingredient slowly or in a controlled manner, for example, using hydroxypropylmethylcellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating a sterilizing agent in the form of a sterile solid composition that may be dissolved in sterile water or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents, and they may be compositions that release the active ingredient only, or preferentially, in a certain part of the gastrointestinal tract, optionally in a delayed manner. Examples of embedded compositions that may be used include polymeric substances and waxes. The active ingredient can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.
[0149] The liquid dosage form suitable for oral administration includes pharma- ceutically acceptable emulsions, lyophilisates for reconstitution, microemulsions, solutions, suspensions, syrups and elixirs.In addition to active ingredients, liquid dosage forms may contain inert diluents commonly used in the art (such as water or other solvents), cyclodextrin and its derivatives, solubilizers and emulsifiers (such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol), oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.
[0150] Besides inert diluents, the compositions of the present invention can also include adjuvants, such as wetting agents, lubricating agents, emulsifying and suspending agents (such as sodium lauryl sulfate and magnesium stearate), or sweetening, flavoring, coloring, perfuming agents, preservatives, or antioxidants.
[0151] Suspensions may contain, in addition to the active compounds, suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
[0152] Formulations of pharmaceutical compositions for rectal, vaginal or urethral administration may be provided as suppositories, which may be prepared by mixing one or more active compounds with one or more suitable non-irritating excipients or carriers including, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which are solid at room temperature but liquid at body temperature and will therefore melt in the rectal or vaginal cavity and release the active compound.
[0153] Formulations of the pharmaceutical composition for buccal administration may be provided as a mouthwash, or as an oral spray or ointment.
[0154] Alternatively, or in addition, the compositions can be formulated for delivery via a catheter, stent, wire, or other intraluminal device, which may be useful for delivery to the bladder, urethra, ureter, rectum, or intestine, among others.
[0155] Formulations suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art.
[0156] Dosage forms for topical or transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharma- ceutically acceptable carrier, and with any preservatives, buffers, or propellants which may be required.
[0157] The ointments, pastes, creams, and gels may contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonite, silicic acid, talc, and zinc oxide, and mixtures thereof.
[0158] Powders and sprays may contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Moreover, sprays can contain customary propellants, such as chlorofluorohydrocarbons, and volatile unsubstituted hydrocarbons, such as butane and propane.
[0159] Alternatively, the compounds described herein can be administered by aerosol. This is accomplished by preparing an aqueous aerosol, a liposomal preparation, or solid particles containing the composition. A non-aqueous suspension (e.g., fluorocarbon propellant) can be used. Sonic nebulizers are preferred because they minimize exposure to shearing agents, which can result in degradation of the compound.
[0160] Usually, aqueous aerosol is made by formulating the aqueous solution or suspension of the drug together with conventional pharmaceutically acceptable carriers and stabilizers.Carriers and stabilizers vary with the needs of a particular composition, but usually include non-ionic surfactants (Tween, Pluronic, sorbitan esters, lecithin, Cremophor), pharmaceutically acceptable cosolvents such as polyethylene glycol, innocuous proteins such as serum albumin, amino acids such as oleic acid, glycine, buffers, salts, sugars or sugar alcohols.Aerosols are generally prepared from isotonic solutions.
[0161] Transdermal patches have the added advantage of providing controlled delivery of the compounds of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the active compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound through the skin. The rate of such flux can be controlled by either providing a rate-controlling membrane or dispersing the compound in a polymer matrix or gel.
[0162] Ophthalmic formulations, eye ointments, powders, solutions, and the like are also considered to be within the scope of the present invention. Exemplary ophthalmic formulations are described in US Patent Publication No. 2005 / 0080056, US Patent Publication No. 2005 / 0059744, US Patent Publication No. 2005 / 0031697, US Patent Publication No. 2005 / 004074, and US Patent No. 6,583,124, the contents of which are incorporated herein by reference. If desired, the liquid ophthalmic formulation has properties similar to those of tears, aqueous humor, or vitreous humor, or can coexist with such fluids. The preferred route of administration is topical administration (e.g., topical administration such as eye drops, or administration via an implant).
[0163] As used herein, the phrases "parenteral administration" and "administered parenterally" refer to forms of administration, usually by injection, excluding enteral and topical administration, including, but not limited to, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intrathecal, and substernal injection and infusion. Pharmaceutical compositions suitable for parenteral administration contain one or more active compounds in combination with one or more pharma- ceutically acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders that can be reconstituted immediately prior to use into a sterile injectable solution or dispersion, which may contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic with the blood of the intended recipient, or suspending or thickening agents.
[0164] As used herein, the phrases "systemic administration," "systemically administered," "peripheral administration," and "peripherally administered" refer to administration of a systemic ligand, drug, or other substance other than directly to the central nervous system, such that it enters the patient's systemic system and thereby undergoes metabolic and other similar processes, e.g., subcutaneous administration.
[0165] Examples of suitable aqueous or non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, ethanol, polyols (glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants.
[0166] These compositions may also contain auxiliary agents, such as preservatives, wetting agents, emulsifying agents, and dispersing agents. Prevention of microbial activity is ensured by the inclusion of various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol sorbic acid, etc. It is also desirable to include isotonic agents, such as sugars, sodium chloride, etc. in the composition. In addition, prolonged absorption of injectable pharmaceutical forms can be brought about by the inclusion of agents that delay absorption, such as aluminum monostearate and gelatin.
[0167] In some cases, in order to prolong the effect of a drug, it is desirable to delay the absorption of the drug from subcutaneous or intramuscular injection.This is accomplished by using a liquid suspension of crystalline or amorphous material that is poorly soluble in water.The rate of absorption of the drug thus depends on its dissolution rate, which in turn may depend on crystal size and crystalline form.Alternatively, delayed absorption of parenterally administered dosage forms is accomplished by dissolving or suspending the drug in an oil vehicle.
[0168] Injectable depot forms are made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer and the nature of the particular polymer used, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Injectable depot formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
[0169] Pharmaceutical preparations can be administered orally, parenterally, topically or rectally. They are, of course, administered in a form suitable for each administration route. For example, they are administered in the form of tablets or capsules, by injection, inhalation, eye drops, ointments, suppositories, infusions, topically by lotions or ointments, and rectally by suppositories. Oral administration is preferred.
[0170] In using the methods of the present invention, the active compound can be administered per se or as a pharmaceutical composition containing, for example, 0.1 to 99.5% (more preferably, 0.5 to 90%) of the active ingredient in combination with a pharma- ceutically acceptable carrier.
[0171] The method of introduction can also be a rechargeable or biodegradable device. A variety of sustained release polymeric devices have been developed and tested in vivo in recent years for the controlled delivery of drugs, including proteinaceous biologics. A variety of biocompatible polymers, including hydrogels, including both biodegradable and non-degradable polymers, can be used to form implants for sustained release of compounds at specific target sites.
[0172] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including, for example, orally, nasally, e.g., by spray, rectally, intravaginally, parenterally, intracisternally, and topically (including buccal and sublingually) by powders, ointments or drops.
[0173] Regardless of the route of administration selected, the compounds may be used in the form of suitable hydrates and / or pharmaceutical compositions of the present invention, but are formulated into pharma- ceutically acceptable dosage forms by conventional methods known to those of skill in the art.
[0174] Actual dosage levels of the active ingredients of the pharmaceutical compositions can be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition and mode of administration, without being toxic to the patient.
[0175] The selected dosage level will depend on a variety of factors, including factors well known in the medical arts, such as the activity of the particular compound or combination of compounds used or their esters, salts or amides, the route of administration, the time of administration, the rate of excretion of the particular compound used, the duration of treatment, other drugs, compounds and / or substances used in conjunction with the particular compound used, the age, sex, weight, condition, general health, and medical history of the patient being treated. In general, the compositions of the invention may be provided in an aqueous solution containing about 0.1-30% w / v of the compounds disclosed herein, among other substances, for parenteral administration. Typical dosage ranges are about 0.01 to about 50 mg / kg body weight per day, administered in a single dose or in 2-4 divided doses. Each divided dose may contain the same or different compounds of the invention.
[0176] A physician or veterinarian of ordinary skill in the art can easily determine and prescribe the therapeutically effective amount of the pharmaceutical composition required. For example, the physician or veterinarian may start the dosage of the pharmaceutical composition or compound at a level lower than that required to achieve the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved. A "therapeutically effective amount" of a compound in this method of treatment refers to the amount of compound in the preparation that, when administered (to a mammal, preferably a human) as part of a desired dosing regimen, alleviates symptoms, improves a condition, or delays the onset of a disease state, for example, at a reasonable benefit / risk ratio applicable to any medical treatment, according to clinically accepted criteria or cosmetic purposes for the disorder or condition being treated. In general, it is understood that an effective amount of a compound will vary with the subject's weight, sex, age, and medical history. Other factors that affect the effective amount include, but are not limited to, the severity of the patient's condition, the disorder being treated, the stability of the compound, and, if desired, another type of therapeutic agent being administered with the compound of the present invention. A larger total dose can be delivered by multiple administrations of the drug. Methods for determining efficacy and dosage are known to those of skill in the art (Isselbacher et al., (1996), Harrison's Principles of Internal Medicine, 13th ed., pp. 1814-1882, incorporated herein by reference).
[0177] In general, a suitable daily dose of an active compound used in the compositions and methods of the invention will be that amount of the compound that is the lowest dose effective to exert a therapeutic effect. Such an effective dose will generally depend upon the factors described above.
[0178] If desired, the effective daily dose of active compound can be administered as 1, 2, 3, 4, 5, 6 or more sub-doses administered separately at appropriate intervals throughout the day, optionally in unit dosage form.In certain embodiments of the present invention, active compound can be administered 2 or 3 times a day.In a preferred embodiment, active compound can be administered once a day.
[0179] The patient to be treated may be any animal in need thereof, including primates, particularly humans, and other mammals such as horses, cattle, pigs and sheep, as well as poultry and pets in general.
[0180] In certain embodiments, the compounds of the present invention can be used alone or administered in conjunction with another type of therapeutic agent. As used herein, the phrase "co-administration" refers to any form of administration of two or more different therapeutic compounds such that the second compound is administered while the previously administered therapeutic compound is still effective in the body (e.g., the two compounds are effective on the patient at the same time, which may involve a synergistic effect of the two compounds). For example, the different therapeutic compounds can be administered either concomitantly or sequentially, either in the same formulation or in separate formulations. In certain embodiments, the different therapeutic compounds can be administered within 1 hour, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, or 1 week of each other. Thus, an individual undergoing such treatment can benefit from the combined effect of the different therapeutic compounds.
[0181] The present invention includes the use of pharma- ceutically acceptable salts of the compounds of the present invention in the compositions and methods of the present invention. In certain embodiments, contemplated salts of the present invention include, but are not limited to, alkylammonium salts, dialkylammonium salts, trialkylammonium salts, or tetraalkylammonium salts. In certain embodiments, contemplated salts of the present invention include, but are not limited to, L-arginine, benentamine, benzathine, betaine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2-(diethylamino)ethanol, ethanolamine, ethylenediamine, N-methylglucamine, hydrabamine, 1H-imidazole, lithium, L-lysine, magnesium, 4-(2-hydroxyethyl)morpholine, piperazine, potassium, 1-(2-hydroxyethyl)pyrrolidine, sodium, triethanolamine, tromethamine, and zinc salts. In certain embodiments, contemplated salts of the present invention include, but are not limited to, Na, Ca, K, Mg, Zn, or other metal salts.
[0182] Pharmaceutically acceptable acid addition salts can also exist as various solvates with water, methanol, ethanol, dimethylformamide, dimethylsulfoxide, etc. Mixtures of such solvates can also be prepared. Such solvates can be from the solvent of crystallization, can be inherent in the solvent of preparation or crystallization, or can be adventitious to such solvent. In some embodiments, the solvates of the disclosed compounds can be dimethylsulfoxide solvates.
[0183] Wetting agents, emulsifying agents and lubricants (such as sodium lauryl sulfate and magnesium stearate), as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition.
[0184] Examples of pharma- ceutically acceptable antioxidants include: (1) water-soluble antioxidants (such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.); (2) oil-soluble antioxidants (such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, α-tocopherol, etc.); and (3) metal chelators (such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.).
[0185] Having now generally described the invention, the same will be more readily understood by reference to the following examples, which are included solely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to be limiting of the invention. EXAMPLES
[0186] Analytical methods for Examples 1 to 5 X-ray powder diffraction X-ray powder diffraction patterns were collected on a Bruker D8 diffractometer using Cu Kα radiation (40 kV, 40 mA), a θ-2θ goniometer, and a divergence of V4 and receiving slits, a Ge monochromator, and a Lynxeye detector. Instrument performance was checked using a certified corundum standard (NIST 1976). The software used for data collection was Diffrac Plus XRD Commander v2.6.1, and data were analyzed and presented using Diffrac Plus EVA v15.0.0.0.
[0187] Samples were prepared as flat specimens using the powders provided under ambient conditions. The samples were gently packed into cavities cut into polished zero-background (510) silicon wafers. The samples were rotated in their own plane during the analysis. Data collection details were as follows: - Angle range: 2~42°2θ - Step size: 0.05° 2θ - Collection time: 0.5 seconds / step
[0188] HPLC Purity analyses were performed using the methods detailed below in Table 1 on an Agilent HP1100 series system equipped with a diode array detector and using ChemStation software vB.04.03.
[0189] [Table 1]
[0190] Polarized Light Microscope (PLM) The samples were examined with a Leica LM / DM polarizing microscope equipped with a digital video camera for image capture. A small amount of each sample was placed on a glass slide, fixed with immersion oil, and covered with a glass slip to separate individual particles as much as possible. The samples were viewed with appropriate magnification and partial polarized light, with a gamma false color filter attached.
[0191] [Example 1] Synthesis of Form 1 by crystallization from methanol Amorphous nicotinamide mononucleotide (565 mg) was weighed into a glass vial and methanol (10.0 mL) was added. The resulting slurry was stirred at room temperature for 4 hours, then an additional portion of MeOH (10.0 mL) was added. The white solid present was isolated by filtration and then dried under vacuum at room temperature for approximately 16 hours to give crystalline β-nicotinamide mononucleotide Form 1, as shown by XRPD analysis (459 mg, 81% recovery).
[0192] [Example 2] Synthesis of Form 1 by crystallization from water Amorphous β-nicotinamide mononucleotide (605 mg) was weighed into a glass vial and deionized water (600 μL) was added. After brief vortexing, a clear solution formed. A portion of this solution (approximately 200 μL) was dispensed into separate vials and chilled at 5° C. for approximately 16 hours. The resulting white solid was isolated by filtration and was shown by XRPD analysis to be crystalline β-nicotinamide mononucleotide Form 1 (yield not determined).
[0193] [Example 3] Synthesis of Form 1 by vapor diffusion for SCXRD Amorphous β-nicotinamide mononucleotide (605 mg) was weighed into a glass vial and deionized water (600 μL) was added. After brief vortexing, a clear solution was formed. A portion of this solution (100 μL) was dispensed into a separate vial, which itself was placed into a larger vial containing methanol (500 μL) allowing vapor to freely diffuse between both vials. The larger vial was sealed and stored at room temperature for approximately 16 hours, from which time a white solid appeared. The solid was sampled and shown by SCXRD to be crystallized β-nicotinamide mononucleotide Form 1.
[0194] [Example 4] Synthesis of Form 2 Amorphous β-nicotinamide mononucleotide (568 mg) was weighed into a glass vial and DMSO (10.0 mL) was added. The resulting slurry was stirred at room temperature for approximately 20 hours. The white solid present was then isolated by filtration, washed with acetone (3×1 mL) and dried under vacuum at room temperature for approximately 16 hours to give crystalline β-nicotinamide mononucleotide Form 2 (501 mg, 72% recovery*). *Based on the assumption that the material is a DMSO monosolvate
[0195] [Example 5] 3-Month Stability Test and Forced Degradation Study for Amorphous and Crystalline NMN Samples of amorphous NMN and NMN crystal form 1 were stored as solids at 25° C. / 0% relative humidity (RH) and 40° C. / 75% RH for three months. Samples were prepared in duplicate with a two week offset. Each replicate was stored in a different container.
[0196] Replicate 1 was placed in an open HPLC vial that was placed in a sealed scintillation vial containing a saturated solution of the relevant inorganic salt (Table 2). These samples were analyzed by HPLC, 1H NMR, XRPD and polarized light microscopy (PLM) at the following time points: 4 weeks, 8 weeks, and 12 weeks.
[0197] Replicate 2 was stored in a sealed box with recipients containing saturated solutions of relevant inorganic salts (Table 2). These samples were analyzed by HPLC at time points of 2, 6, 10, and 12 weeks. Samples at 25°C / 0% RH were stored in a sealed box containing a desiccant (P2O5).
[0198] [Table 2]
[0199] The amorphous material remained unchanged in terms of solid and particulate morphology after 12 weeks of storage at 25° C. and 0% RH. A decrease in purity was observed from 98.2% (time 0) to 95.5% (time week 12). The major increasing impurity observed by HPLC eluted with an RRT of 1.73 and corresponded to nicotinamide (2.8% at the week 12 time point). (See Tables 3 and 4.)
[0200] [Table 3]
[0201] The amorphous material crystallized to give Form 1 in needle-like morphology when stored at 25% or higher relative humidity. Chemical purity was shown to decrease under all test conditions, especially upon storage at 40°C / 75%RH. The main increasing impurity observed was also nicotinamide (RRT=1.73). The purity of the material after 12 weeks at 40°C / 75%RH was determined as 67.5% (replicate 2) with nicotinamide present at 20.6%.
[0202] Crystalline Form 1 remained unchanged in terms of solid and particulate morphology in all test conditions. The material remained chemically pure (approximately 99.3%) after 4 weeks of storage in all test conditions. A slight decrease in purity was observed beyond 4 weeks. Storage at 25°C / 0% RH proved to be the most favorable condition for sample stability as analysis after 12 weeks showed the sample had a purity of 98.9% and nicotinamide 0.38%. The greatest change in purity was observed in samples stored at elevated temperature (40°C) or humidity (75% RH, 97% RH). Purity decreased from 99.5% to 95.8% after 12 weeks at 25°C / 97% RH and 90.7% after 12 weeks at 40°C / 75% RH. The most prevalent impurity in all conditions was nicotinamide (RRT=1.73 min). This impurity increased from 0.12% (time 0) to 3.46% after 12 weeks at both 40°C / 75% RH and 25°C / 97% RH.
[0203] The HPLC results were consistent within the replicates, although more rapid degradation was observed in replicate 1. A potential influence could be the smaller size of the containers, which would require less time to equilibrate to the corresponding storage conditions. Tables 4-7 provide the results obtained from replicate 1 and replicate 2.
[0204] [Table 4]
[0205] [Table 5]
[0206] [Table 6]
[0207] [Table 7]
[0208] Incorporation by Reference All publications and patents mentioned herein are herein incorporated by reference in their entirety to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In the case of conflict, the present specification, including definitions herein, will control.
[0209] Equivalent While specific embodiments of the invention have been discussed, the above specification is illustrative and not restrictive. Many variations of the invention will become apparent to those skilled in the art from this specification and the claims that follow. The full scope of the invention should be determined by reference to the specification, along with the claims and such variations, along with their full scope of equivalents.
Claims
1. Formula (I) 【Chemistry 1】 A crystalline compound having the structure:
2. 10. The crystalline compound of claim 1, which is anhydrous.
3. 3. The crystalline compound of claim 2 having 2θ values of 20.03, 20.14, 21.83, and 25.
73.
4. 4. The crystalline compound of claim 3 having 2θ values of 20.03, 20.14, 21.03, 21.83, 23.08, 23.39, 25.73, and 26.
59.
5. 5. The crystalline compound of claim 4 having 2θ values of 7.70, 11.54, 12.64, 16.03, 18.99, 20.03, 20.14, 20.83, 21.03, 21.83, 23.08, 23.39, 25.48, 25.73, 26.59, and 29.
78.
6. 6. The crystalline compound of claim 5 having 2θ values of 7.70, 9.95, 11.54, 12.64, 16.03, 18.18, 18.99, 19.16, 19.44, 20.03, 20.14, 20.83, 21.03, 21.83, 22.44, 23.08, 23.39, 23.89, 24.08, 24.53, 24.68, 25.05, 25.48, 25.73, 26.08, 26.59, 27.33, 27.67, 29.78, and 29.
92.
7. 7. The crystalline compound of claim 6 having an XRD pattern substantially as shown in FIG. 1, labeled Form 1.
8. 2. The crystalline compound of claim 1 which is a dimethylsulfoxide solvate.
9. 9. The crystalline compound of claim 8 having 2θ values of 8.29, 17.39, 19.54, 22.78, and 22.
98.
10. 10. The crystalline compound of claim 9 having 2θ values of 8.29, 17.39, 19.54, 19.74, 20.98, 21.58, 22.03, 22.78, 22.98, and 25.
53.
11. 11. The crystalline compound of claim 10 having 2θ values of 8.29, 16.10, 17.39, 19.24, 19.54, 19.74, 20.33, 20.78, 20.98, 21.18, 21.58, 22.03, 22.78, 22.98, 25.53, 28.48, and 29.
48.
12. 12. The crystalline compound of claim 11 having 2θ values of 8.29, 13.12, 15.79, 16.10, 16.69, 17.39, 19.03, 19.24, 19.54, 19.74, 20.33, 20.78, 20.98, 21.18, 21.58, 22.03, 22.78, 22.98, 23.95, 24.14, 24.48, 24.64, 25.14, 25.53, 25.87, 26.89, 27.18, 27.67, 28.02, 28.13, 28.48, 28.98, 29.34, 29.48, and 29.
92.
13. 13. The crystalline salt of claim 12 having an XRD pattern substantially as shown in FIG. 1, labeled Form 2.
14. 14. A pharmaceutical composition comprising a salt according to any one of claims 1 to 13 and one or more pharma- ceutically acceptable excipients.
15. Formula (I): 【Chemistry 2】 A method for producing a crystalline compound having the structure a) providing a mixture of a compound of formula (I) in a solvent; and b) crystallizing the compound of formula (I) from a mixture containing the compound of formula (I); The method includes:
16. 16. The method of claim 15, wherein the crystalline compound is anhydrous.
17. 16. The method of claim 15, wherein the crystalline compound is a solvate.
18. 18. The method of claim 17, wherein the solvate is a dimethylsulfoxide solvate.
19. 16. The method of claim 15, wherein the solvent is methanol or water.
20. 19. The method of claim 18, wherein the solvent is dimethylsulfoxide.
21. 21. The method of any one of claims 15 to 20, wherein the mixture comprising the compound of formula (I) is a solution and the step of crystallizing the compound of formula (I) from the mixture comprises the step of supersaturating the solution to cause the compound of formula (I) to precipitate from the solution.
22. 22. The method of claim 21 , wherein the step of supersaturating the solution comprises gently adding an anti-solvent, cooling the solution, reducing the volume of the solution, or any combination thereof.
23. 22. The method of claim 21, wherein the step of supersaturating the solution comprises cooling the solution to below ambient temperature.
24. 21. The method of any one of claims 15 to 20, wherein the mixture comprising the compound of formula (I) is a slurry.
25. 25. The method of any one of claims 15 to 24, further comprising isolating the crystalline compound.
26. 26. The method of claim 25, wherein isolating the crystalline compound comprises filtering the crystalline compound from the mixture.
27. 27. The method of claim 25 or claim 26, further comprising drying the crystalline compound under reduced pressure.
28. 28. The method of any one of claims 15 to 27, wherein the crystalline compound is a crystalline compound according to any one of claims 1 to 13.
